Outlook Therapeutics (FRA:41O) Deferred Tax : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Outlook Therapeutics's change in deferred tax for the three months ended in Dec. 2024 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Outlook Therapeutics Deferred Tax Historical Data

The historical data trend for Outlook Therapeutics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Deferred Tax Chart

Outlook Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Deferred Tax

Get a 7-Day Free Trial

Outlook Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Outlook Therapeutics Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Outlook Therapeutics Deferred Tax Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

OTLK:USA

Address

111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines